
    
      This is a multi-center, single-arm, open-label study in patients with hip OA to evaluate a
      procedure for intra-articular injection of FX006 in patients with hip OA. A maximum number of
      approximately 30 patients may be enrolled in this protocol.

      All enrolled patients will receive a single intra-articular (IA) injection on Day 1 and be
      followed for 8 weeks.
    
  